UPDATE : Monday, January 27, 2020
상단여백
Afstyla wins nod as new therapy for hemophilia A by Kim Yun-mi 2020-01-24 08:18
SK Chemicals avoids drug price cut using administrative suit by Kim Yun-mi 2020-01-23 15:24
Sales of antidiabetic SGLT-2 inhibitors grew 40% in 2019 by Kim Yun-mi 2020-01-22 15:10
Some Merck Korea workers commute from provinces to Seoul every day by Kim Yun-mi 2020-01-21 14:21
‘Government should control next-generation sequencing data’ by Kim Yun-mi 2020-01-20 15:47
라인
Pfizer’s spinoff of generics unit causes disputes with trade union by Kim Yun-mi 2020-01-20 15:44
Takeda’s Kynteles expands indication for ulcerative colitis, Crohn’s disease by Kim Yun-mi 2020-01-17 17:30
GSK to target ovarian cancer, multiple myeloma, endometrial cancer by Kim Yun-mi 2020-01-16 14:10
Regulator to mandate long-term follow-up on advanced biopharmaceuticals by Kim Yun-mi 2020-01-15 13:05
Will Steglatro prove SGLT-2 inhibitor’s cardiovascular benefits? by Kim Yun-mi 2020-01-14 15:28
라인
Zejula widens indication as monotherapy for ovarian cancer by Kim Yun-mi 2020-01-13 16:25
Lilly secures atopic dermatitis drug through Dermira acquisition by Kim Yun-mi 2020-01-13 14:05
Latecomer Bavencio improves overall survival in bladder cancer trial by Kim Yun-mi 2020-01-10 14:23
Regulator to help Korean firms’ global biz through international cooperation by Kim Yun-mi 2020-01-08 16:33
Eliquis price cut delayed amid prolonged administrative suit by Kim Yun-mi 2020-01-07 11:32
라인
BioMarin seeks license for gene therapy to treat hemophilia by Kim Yun-mi 2020-01-06 16:44
Tau, rather than amyloid, may cause Alzheimer’s disease by Kim Yun-mi 2020-01-06 14:13
[New Year Special] Investors vulnerable to risky biotech business by Kim Yun-mi 2020-01-02 17:35
Multinational pharmaceuticals' rush to merge face union backlash in Korea by Kim Yun-mi 2019-12-29 10:54
‘No-Japan’ campaign cause anxiety among Japanese pharmaceutical firms by Kim Yun-mi 2019-12-27 12:08
여백
여백
여백
Back to Top